BioCentury | Jan 12, 2021

Sanofi joins the myeloid checkpoint movement with Biond deal

...I studies. Until this week, next-generation checkpoint inhibitors were absent from the clinical pipeline. TARGETSHLA-G – Major histocompatibility complex class I...
BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

...the CAR into TRAC to prevent GvHD, CTX110 has a CRISPR-mediated B2M knockout for elimination MHCI...
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

...necrosis factor receptor superfamily member 9HLA-G – Major histocompatibility complex class I...
BioCentury | Aug 6, 2020
Emerging Company Profile

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

Versant’s Ridgeline incubator in Basel has launched Matterhorn with an off-the-shelf MR1T cell therapy designed to address a broader range of cancers than CAR T and TCR therapies. The company raised a $30 million series...
BioCentury | Jul 21, 2020

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

...of cash from Tizona. Targets HLA-G - Major histocompatibility complex class I G Paul Bonanos, Associate Editor Tizona Therapeutics Inc. Gilead Sciences Inc. Major histocompatibility complex class I...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

...disease. Computational tools that predict TCR-antigen interactions are generally more advanced for antigens presented on MHCI...
...Pioneering, JDRF T1D Fund CEO: John Cox Targets MHC - Major histocompatibility complex MHCI - Major histocompatibility complex class I...
BioCentury | Jan 25, 2020
Preclinical News

Ervaxx pursues non-peptide tumor antigens via Cardiff University TCR, T cell deal

A research collaboration with Cardiff University will enable Ervaxx to go beyond targeting neoantigens derived from typically unexpressed DNA, to tumor antigens that aren’t peptides. Ervaxx Ltd. will fund research, conducted in the lab of...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...Ganglioside GD2 HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 HLA-A2 - Major histocompatibility complex class I...
BioCentury | Nov 15, 2019
Preclinical News

Nov. 14 Preclinical Quick Takes: Gut microbe-targeting phage for alcoholic liver disease; plus Cellectis, Biomica, University of Michigan and Rubius

...Cancer (SITC) meeting in National Harbor, Md. The allogeneic erythrocytes expressing 4-1BBL, IL-12 and an MHCI-displayed...
...Immunotherapy Red ") Targets: 4-1BBL (TNFSF9, CD137L) - 4-1BB ligand; IL-12 - Interleukin-12; MHCI - Major histocompatibility complex class I...
BioCentury | Oct 1, 2019
Company News

ElevateBio launches HighPassBio with TCR immunotherapy focus

...ElevateBio Plans to Create Portfolio of Cell, Gene Therapy Newcos” ). Targets: HLA-A 0201 - Major histocompatibility complex class I...
...HA-1; HLA-HA1) - Histocompatibility minor HA-1 Elizabeth S. Eaton, Staff Writer ElevateBio LLC Histocompatibility minor HA-1 (HMHA1) (HA-1) (HLA-HA1) Major histocompatibility complex class I...
Items per page:
1 - 10 of 197